From leading role to the backstage: mesenchymal stem cells as packaging cell lines for in situ production of viral vectors.
Gene therapy is based on the genetic manipulation of target cells. The genetic information required to genetically engineer these cells can be delivered through non-viral or viral vectors that present different biologic properties. The production of viral vectors for gene therapy depends on the nature of the cells transfected with plasmids containing the genetic information for recombinant viral assemblage. These so-called packaging cell lines (PCL) can be injected into the target organ, for the in situ transduction of target cells. There have been recent reports about the capacity of mesenchymal stem cells (MSCs) to target tumor cells. Different research groups, including our own, have isolated these MSCs, but they have not yet been studied as potential PCL to produce viral vectors. We propose here that a MSC packaging cell line could be employed for in situ gene therapy of solid tumors. The tropism of MSCs for tumor cells may render this PCL more efficient in that microenvironment, producing viral vectors for longer periods of time, shifting MSCs from target cell to the backstage level of viral gene therapy.
Silva
F H
FH
Genetics Department, Universidade Federal do Rio Grande do Sul, Av Bento Gonçalves 9500, 91501-970 Porto Alegre, RS, Brazil.
Nardi
N B
NB
D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D002460:Cell Line; D004279:DNA, Viral / Q000235:genetics; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D059630:Mesenchymal Stem Cells / Q000166:cytology* / Q000502:physiology; D008954:Models, Biological; D012367:RNA, Viral / Q000235:genetics; D012190:Retroviridae / Q000235:genetics*; D019065:Virus Assembly
D004279:DNA, Viral; D012367:RNA, Viral